Abstract
Drug-induced subacute cutaneous lupus erythematosus (SCLE) is associated with use of the following classes of medications: anti-hypertensives, anti-cholesterolemia, anti-psychotics, and anti-inflammatory drugs. Docetaxel is an anti-neoplastic agent, which is widely used for treatment of non-small cell lung cancer. Few cases of docetaxel-induced SCLE have been reported in the medical literature. Here, we report the case of a 58-year-old female patient who developed drug-induced SCLE after administration of docetaxel. After 4 cycles of chemotherapy with docetaxel and cisplatin, erythematous skin eruptions developed on the patient's face. Skin biopsies of the eruptions were remarkable for interfacing dermatitis with basement membrane thickening. Immunofluorescent study revealed characteristic features of SCLE, including granular deposition of IgM, C3, and apoptotic bodies along the basement membrane. The skin eruptions resolved gradually after cessation of drug and with the use of topical corticosteroids.
비소세포폐암의 일차치료로 사용되고 있는 항암치료제인 docetaxel은 세포주기 정체를 통한 세포자멸을 야기하는 약제로 이로 인한 누클리오좀 유리가 약제유발 홍반루푸스의 원인으로 추정되고 있으나 실제 docetaxel로 야기된 아급성 피부 홍반루푸스의 증례는 지금까지 전세계적으로 4명의 증례 보고만이 있을 뿐이며 국내에서는 아직까지 보고된 바가 없다. 저자들은 비소세포폐암 환자에서 docetaxel과 cisplatin 병합 항암 화학요법 도중 발생한 아급성 피부 홍반루푸스 1예를 경험하였기에 이를 보고하는 바이다.
